Current Issues of Pharmacy and Medical Sciences

Assessment of MT-279 compound effect on physical endurance of rats under conditions of chronic hypokinesia

Curr Issues Pharm Med Sci., Vol. 30, No. 3, 134-134

Andrii Saienko1, Natalia Voloshchuk1, Olena Toziuk2
Olena Kryvoviaz2, Serhii Kryvoviaz3, Vasyl Koval2

Department of Pharmacology, National Pyrogov Memorial Medical University, Vinnytsia, Pyrogov 56, Vinnytsia, Ukraine
2 Department of Pharmacy, National Pyrogov Memorial Medical University, Vinnytsia, Pyrogov 56, Vinnytsia, Ukraine
3 Department of Eye Diseases, National Pyrogov Memorial Medical University, Vinnytsia, Pyrogov 56, Vinnytsia, Ukraine

DOI: https://doi.org/10.1515/cipms-2017-0024

Abstract

 The objective of the study was to assess the effect of a sodium salt 3-(2-oxo-3-phenyl- 2H-[1,2,4]triazine[2,3-c]quinazolin-6-yl) of propanoic acid (MT-279 compound) on physical endurance of rats under conditions of chronic hypokinesia (15 days) in comparison with 2-ethylthiobenzimidazole hydrobromide (2-ETBI). The results of the conducted experiment showed that chronic hypokinesia (15 days) caused a progressive decrease in the physical endurance of animals. The signs of this phenomenon occurred already on the Day 7 of the experiment. It manifested by a significant decrease in the duration of rats swimming, treadmill runtime and holding on rotating rods (rotarod test). The course of MT-279 compound (2.5 mg/kg, ip) administered to animals in the specified experimental conditions contributed to restoration of physical performance of the study subjects. Upon introduction of the compound, the duration of rats` swimming on Day 7 of the experiment increased by 108.2%, and on Day 15 - by 64.2%. Administration of 2-ETBI caused the growth of this indicator by 70.5% and 24.2%, respectively. Along with this, we revealed an increase of rats` treadmill running time. On Day 7 and Day 15 of the experiment, we recorded 55.2% and 68.4% growth of the indicator, respectively. Daily administration of 2-ETBI contributed to 41.7% and 59.7% increase of running time, respectively. On Day 7 of MT-279 compound administration under the conditions of chronic hypokinesia, the duration of rats` rod retention time increased by 58.7% compared to 6.2% for 2-ETBI. On Day 15 of the experiment, the physical endurance of animals assessed under this test compared to the control group was 89.0% and 72.3%, respectively. On Day 7, MT-279 compound was significantly superior to the comparator drug in all tests performed for assessment of the ability to improve physical endurance under conditions of chronic hypokinesia. On Day 15 of study, the statistically significant superiority of MT-279 compound over 2-ETBI was identified in all forced swimming and rotarod tests.

Full text


Keywords

chronic hypokinesia; physical endurance; actoprotectors; quinazoline derivatives; 2-ethylthiobenzimidazole hydrobromide

Calendar

July 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31